Invasive fungal infections are associated with high morbidity and mortality, and often disproportionately affect immunocompromised patients. Because there are a limited number of currently FDA-approved antifungals, treatment choices can be difficult. This is especially true for special populations (like children) or in cases of antifungal resistance. This series will explore strategies for the management of invasive fungal infections.
Review
The purpose of this review is to discuss resistance mechanisms and challenges with currently available agents, provide evidence for combination therapy, and evaluate the newly available and upcoming antifungal agents and their proposed place in the treatment of challenging fungal infections.
